This Article Full Text (OnlineFirst PDF) All Versions of this Article: 1756283X09336045v1 2/4/205    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Pawlotsky, J.-M. Social Bookmarking                         What's this?

Therapeutic implications of hepatitis C virus resistance to antiviral drugs

^* To whom correspondence should be addressed. E-mail: jean-michel.pawlotsky{at}hmn.aphp.fr.

	Abstract

Treatment of chronic hepatitis C is currently based on a combination of pegylated interferon- and ribavirin. Neither drug exerts direct selective pressure on viral functions, meaning that interferon-/ribavirin treatment failure is not due to selection of interferon-- or ribavirin-resistant viral variants. Several novel antiviral approaches are currently in preclinical or clinical development, and most target viral enzymes and functions, such as hepatitis C virus protease and polymerase. These new drugs all potentially select resistant viral variants both in vitro and in vivo, and resistance is therefore likely to become an important issue in clinical practice.

First published on June 4, 2009, doi:10.1177/1756283X09336045

Therapeutic Advances in Gastroenterology 2009;2:205.

A more recent version of this article appeared on July 1, 2009


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?